Tricaprin from Coconut Oil Offers Hope for Patients with Heart Disease

Medical News: Heart disease is a leading cause of death worldwide, affecting millions each year. While some forms of heart disease are well-known and extensively studied, new conditions continue to emerge, presenting challenges for diagnosis and treatment. One such condition is Triglyceride Deposit Cardiomyovasculopathy (TGCV), a relatively recently identified heart disease that affects the ability of heart muscle cells to break down triglycerides. This impaired fat metabolism leads to severe heart complications, including heart failure, coronary artery disease, and even life-threatening arrhythmias.


Tricaprin from Coconut Oil Offers Hope for Patients with Heart Disease

Researchers from Osaka University and Osaka University Hospital in Japan have been investigating potential treatments for TGCV, and their findings offer a new ray of hope. Their studies have demonstrated that a natural supplement called tricaprin - a medium-chain triglyceride (MCT) found in foods like coconut oil and dairy products - may significantly improve long-term survival rates and heart function in patients with TGCV. These findings open new doors for potential treatment options for this rare and debilitating disease.
 
Understanding Triglyceride Deposit Cardiomyovasculopathy (TGCV)
TGCV is not a common heart disease, but its effects can be devastating. Unlike traditional heart conditions, which often result from cholesterol buildup, TGCV is characterized by the accumulation of triglycerides - another type of fat - within the heart muscle and the smooth muscle cells lining the blood vessels. This fat accumulation is a result of defective intracellular lipolysis, meaning that cells cannot efficiently break down triglycerides for energy. As a result, fat builds up in the heart muscle, leading to energy shortages, cell dysfunction, and progressive heart failure.
 
The disease primarily affects adults and is often diagnosed in middle-aged or older individuals. Some cases have been linked to genetic mutations, while others develop without a clear genetic cause. TGCV has been observed in patients with diabetes and those undergoing dialysis, suggesting a possible link between metabolic disorders and the disease.
 
This Medical News report explores the latest research on TGCV, particularly the promising role of tricaprin in treating this condition. Researchers believe that addressing the fat accumulation in heart cells could be key to improving outcomes for affected patients.
 
The Role of Tricaprin in Treating TGCV
Tricaprin is a type of medium-chain triglyceride (MCT) that can be found in certain natural sources like coconut oil, dairy products, and MCT oil. Unlike long-chain triglycerides, which require complex metabolic processing, MCTs are rapidly absorbed and utilized by the body as an energy source. Because of this unique property, tricaprin has been studied for its potential to help patients with TGCV by improving the breakdown of accumulated triglycerides within heart cells.
In previous research, tricaprin supplementation has shown promise in promoting triglyceride metabolism and restoring cellular energy production in heart tissue. This encouraged researchers at Osaka University to further investigate its impact on long-term survival and heart function in TGCV patients.
 
Key Findings from the Recent Study
The latest study, published in Nature Cardiovascular Research, examined patient data from multiple hospitals across Japan. The study included 22 patients diagnosed with TGCV who received tricaprin supplementation and 190 control patients who did not. The control group was carefully selected to ensure that the comparison was as accurate as possible, with 81 of the control patients matched to the tricaprin group based on age, disease severity, and other health factors.
 
The study focused on several key aspects, including heart function, lipid metabolism, and overall survival rates. The results were striking:
 
-Improved Heart Function: Patients who received tricaprin supplementation exhibited significant improvements in their heart’s ability to pump blood. Echocardiographic studies showed enhanced left ventricular function, including better ejection fraction (the percentage of blood pumped out of the heart with each contraction) and positive remodeling of the heart muscle.
 
-Fat Breakdown and Energy Restoration: Tests measuring myocardial lipolysis, or the heart muscle’s ability to break down fat, showed substantial improvement in patients taking tricaprin. This suggests that the supplement effectively enhanced intracellular fat metabolism, reversing the detrimental triglyceride buildup.
 
-Higher Long-Term Survival Rates: The most notable finding was the improvement in patient survival. Among those receiving tricaprin, the three-year and five-year survival rates were 100%. In contrast, the control group had a 78.6% survival rate at three years and a 68.1% survival rate at five years.
 
-Recovery in Heart Failure Patients: The study also analyzed a subset of patients who had heart failure. Among these patients, 14 in the intervention group and 128 in the control group were compared. Again, tricaprin supplementation resulted in 100% three-year and five-year survival rates, while the control group had lower survival rates of 76.8% at three years and 64.8% at five years.
 
-Reversal of Symptoms in Severe Cases: Some patients who had been hospitalized multiple times for worsening heart failure before starting tricaprin treatment showed remarkable recovery, maintaining stable heart function for years without requiring additional hospitalizations.
 
Real-Life Cases Demonstrating Tricaprin’s Benefits
A particularly compelling case involved a woman in her 50s who had been hospitalized five times over 18 months due to worsening heart failure. Despite receiving multiple conventional heart failure treatments, her condition did not improve. She also suffered from chronic kidney disease and required dialysis. After starting tricaprin supplementation, her heart function significantly improved, and she remained stable for more than seven years, avoiding further hospitalizations. This dramatic improvement highlights tricaprin’s potential in reversing heart damage even in patients with advanced disease.
 
Potential Implications for Other Heart Conditions
The study’s findings may have broader implications for other forms of heart failure. Fat accumulation in heart cells is commonly observed in various types of heart disease, raising the possibility that tricaprin’s effects could extend beyond TGCV patients.
 
Researchers believe that future studies should explore whether tricaprin supplementation could benefit a wider population of heart failure patients, particularly those with metabolic disorders or high triglyceride levels. If further research confirms its effectiveness, tricaprin could become a novel therapeutic option for individuals at risk of heart failure due to lipid metabolism issues.
 
Conclusion
The discovery of tricaprin’s role in improving heart function and survival in TGCV patients represents a major breakthrough in cardiovascular medicine. By addressing the underlying fat accumulation in heart cells, tricaprin offers a promising and potentially life-saving treatment for individuals affected by this rare but serious disease. The study findings demonstrate that tricaprin supplementation leads to significant improvements in heart function, reverses symptoms of heart failure, and dramatically increases long-term survival rates.
 
Given the promising results observed in TGCV patients, further research is needed to determine whether tricaprin could be used to treat other heart conditions involving lipid metabolism dysfunction. If future studies confirm its broader benefits, tricaprin may emerge as a valuable addition to heart failure treatment strategies worldwide.
 
The study findings were published in the peer-reviewed journal: Nature Cardiovascular Research.
https://www.nature.com/articles/s44161-025-00611-7
 
For the latest on heart diseases, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/vitisin-a-from-aged-red-wine-found-to-be-more-effective-than-cyanidin-3-o-glucoside-in-reducing-triglyceride-levels
 
https://www.thailandmedical.news/news/thailand-medical-study-finds-fermented-houttuynia-cordata-juice-protects-against-heart-inflammation-and-damage-in-sepsis
 
https://www.thailandmedical.news/news/bulgarian-study-highlights-benefits-of-black-chokeberry-juice-for-heart-health
 
https://www.thailandmedical.news/pages/thailand_doctors_listings
 
https://www.thailandmedical.news/pages/thailand_hospital_listings